Literature DB >> 18371485

Identification and viability assessment of infarcted myocardium with late enhancement multidetector computed tomography: comparison with thallium single photon emission computed tomography and echocardiography.

Kuan-Rau Chiou1, Chun-Peng Liu, Nan-Jing Peng, Wei-Chun Huang, Shih-Hung Hsiao, Yi-Luan Huang, Kuen-Huang Chen, Ming-Ting Wu.   

Abstract

BACKGROUND: Recent studies revealed that multidetector computed tomography late enhancement (MDCT-LE) is a reliable technique for detecting necrotic and scarred myocardial tissue. The aims of the study were to identify infarcted myocardium using MDCT-LE protocol in patients after myocardial infarction (MI) and assess viability in resting wall motion abnormalities.
METHODS: One hundred one patients with previous MI (62 +/- 13 years, 1-6 months after MI) underwent MDCT-LE (15 minutes after contrast medium administration), rest-redistribution thallium single photon emission computed tomography (Tl-SPECT), and dobutamine echocardiography (DbE). In a 17-segment model, infarcted myocardium detected by MDCT-LE was categorized as none, 1%-25%, 26%-50%, 51%-75%, or >75% segmental extent and was compared with decreased uptake of Tl-SPECT and contractile function by DbE on per patient and segmental basis in a blinded fashion.
RESULTS: By per patient analysis, MDCT-LE identified the presence of infarcted myocardium in 97 patients (96%), and Tl-SPECT decreased uptake in 88 patients (87%), (P = .02). By per segment analysis, the concordance for detecting infarcted myocardium was good (kappa value = 0.792). In segments with resting wall motion abnormalities (N = 486), there was moderate concordance in assessing viability (kappa value between MDCT and Tl-SPECT = 0.555, MDCT and DbE = 0.498, Tl-SPECT and DbE = 0.478) with predefined MDCT-LE threshold of 50% segmental extent. Among segments with MDCT-LE >75% segmental extent, the proportion designated nonviable by Tl-SPECT and DbE reached 87.8% and 92.2%, respectively.
CONCLUSIONS: Multidetector computed tomography late enhancement is accurate in identifying the presence and extent of infarcted myocardium. Its segmental extent has good correlation with the magnitude of thallium decreased uptake and can predict contractile reserve. Multidetector computed tomography late enhancement can be an alternative to assess viability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18371485     DOI: 10.1016/j.ahj.2007.11.013

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  Multimodality Imaging of Myocardial Viability.

Authors:  Kinjan Parikh; Alana Choy-Shan; Munir Ghesani; Robert Donnino
Journal:  Curr Cardiol Rep       Date:  2021-01-04       Impact factor: 2.931

2.  Non-linear blending of dual-energy CT data improves depiction of late iodine enhancement in chronic myocardial infarction.

Authors:  Julian L Wichmann; Xiaohan Hu; J Matthias Kerl; Boris Schulz; Boris Bodelle; Claudia Frellesen; Thomas Lehnert; Thomas J Vogl; Ralf W Bauer
Journal:  Int J Cardiovasc Imaging       Date:  2014-05-09       Impact factor: 2.357

3.  Evaluation of reperfused myocardial infarction by low-dose multidetector computed tomography using prospective electrocardiography (ECG)-triggering: comparison with magnetic resonance imaging.

Authors:  Hye Mi Gweon; Sang Jin Kim; Tae Hoon Kim; Sang Min Lee; Yoo Jin Hong; Se-Joong Rim; Bum Ki Hong; Phil Ki Min; Young Won Yoon; Hyuck Moon Kwon
Journal:  Yonsei Med J       Date:  2010-09       Impact factor: 2.759

Review 4.  Non-invasive imaging in detecting myocardial viability: Myocardial function versus perfusion.

Authors:  Iqbal A Elfigih; Michael Y Henein
Journal:  Int J Cardiol Heart Vasc       Date:  2014-10-18

5.  Myocardial viability: what we knew and what is new.

Authors:  Adel Shabana; Ayman El-Menyar
Journal:  Cardiol Res Pract       Date:  2012-09-05       Impact factor: 1.866

6.  TUSC3 induces autophagy in human non-small cell lung cancer cells through Wnt/β-catenin signaling.

Authors:  Yun Peng; Jun Cao; Xiao-Yi Yao; Jian-Xin Wang; Mei-Zuo Zhong; Ping-Ping Gan; Jian-Huang Li
Journal:  Oncotarget       Date:  2017-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.